Actively Recruiting

Phase 2
Age: 18Years - 75Years
MALE
NCT06259123

Neoadjuvant PSMA-RLT in Oligometastatic PCa

Led by Medical University of Vienna · Updated on 2024-02-15

10

Participants Needed

1

Research Sites

173 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Prospective single-center phase II study to evaluate the PSA, imaging and pathological response, as well as oncological outcomes of systemic radioligand therapy \[177Lu\]Lu-PSMAI\&T (PSMA-RLT) in patients planned for radical prostatectomy (RP) for oligometastatic prostate cancer (PCa) diagnosed using \[68Ga\]Ga-PSMA-11 PET examination. Ten patients with oligometastatic primary PCa diagnosed using \[68Ga\]Ga-PSMA-11 PET-CT/MRI imaging will be included in this study.

CONDITIONS

Official Title

Neoadjuvant PSMA-RLT in Oligometastatic PCa

Who Can Participate

Age: 18Years - 75Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Oligometastatic prostate cancer diagnosed by [68Ga]Ga-PSMA-11 imaging with M1a and/or M1b positive and 5 or fewer bone metastases and/or M1c with 3 or fewer lung metastases
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Adequate bone marrow function with WBC 1.5 x 10^9/L, platelets 100 x 10^9/L, and hemoglobin 9 g/dL
  • Adequate kidney function with eGFR 50 mL/min/1.73 m^2 and albumin level 2.5 g/dL
  • Ability to sign informed consent form
Not Eligible

You will not qualify if you...

  • Participation in another interventional trial
  • Severe cancer or medical conditions limiting life expectancy beyond the trial duration
  • Nonmetastatic prostate cancer on [68Ga]Ga-PSMA-11 imaging
  • More than 5 bone metastases on [68Ga]Ga-PSMA-11 imaging
  • Visceral metastases except for lungs
  • Age over 75 years
  • Current or prior androgen deprivation therapy with agonists or antagonists
  • Clinically significant somatic or psychiatric diseases affecting study objectives or assessments
  • Complete urinary outflow obstruction or severe unmanageable urinary incontinence

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Medical University of Vienna

Vienna, Austria, 1090

Actively Recruiting

Loading map...

Research Team

S

Sazan Rasul, PhD

CONTACT

S

Shahrokh F. Shariat, Professor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Neoadjuvant PSMA-RLT in Oligometastatic PCa | DecenTrialz